Current Vascular Pharmacology
Title:Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Volume: 12 Issue: 6
Author(s): Vasilios G. Athyros, Niki Katsiki and Asterios Karagiannis
Affiliation:
Keywords: Heart failure with reduced ejection fraction, valsartan, AHU-377, LCZ696, survival, hospitalization.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Katsiki Niki and Karagiannis Asterios, Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?), Current Vascular Pharmacology 2014; 12 (6) . https://dx.doi.org/10.2174/157016111206141210114716
DOI https://dx.doi.org/10.2174/157016111206141210114716 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Statin-induced Vascular Smooth Muscle Cell Apoptosis: A Possible Role in the Prevention of Restenosis?
Current Drug Targets - Cardiovascular & Hematological Disorders The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design Dabigatran: The Anticoagulant We have Long Expected?
Recent Patents on Cardiovascular Drug Discovery Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews Silencing of MiRNA-126 in Kidney Ischemia Reperfusion is Associated with Elevated SDF-1 Levels and Mobilization of Sca-1+/Lin- Progenitor Cells
MicroRNA The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Synthesis, Stereochemical Studies and Antimycobacterial Activity of New Acetyl- Hydrazine Pyridazinones
Current Organic Synthesis The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension:Where Do We Go from Here?
Reviews on Recent Clinical Trials Pharmacological Activities and Therapeutic Potential of Kaempferitrin in Medicine for the Treatment of Human Disorders: A Review of Medicinal Importance and Health Benefits
Cardiovascular & Hematological Disorders-Drug Targets Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets